These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28000522)

  • 1. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.
    Greth W; Robbie GJ; Brohawn P; Hultquist M; Yao B
    Immunotherapy; 2017 Jan; 9(1):57-70. PubMed ID: 28000522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
    Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
    Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon α-targeted therapy.
    Hanaoka H; Takeuchi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):181-8. PubMed ID: 23994795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting interferons in systemic lupus erythematosus: current and future prospects.
    Mathian A; Hie M; Cohen-Aubart F; Amoura Z
    Drugs; 2015 May; 75(8):835-46. PubMed ID: 25940912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations.
    Anderson E; Furie R
    Immunotherapy; 2020 Apr; 12(5):275-286. PubMed ID: 32237942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
    Petri M; Wallace DJ; Spindler A; Chindalore V; Kalunian K; Mysler E; Neuwelt CM; Robbie G; White WI; Higgs BW; Yao Y; Wang L; Ethgen D; Greth W
    Arthritis Rheum; 2013 Apr; 65(4):1011-21. PubMed ID: 23400715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type I interferon blockade in systemic lupus erythematosus: where do we stand?
    Lauwerys BR; Ducreux J; Houssiau FA
    Rheumatology (Oxford); 2014 Aug; 53(8):1369-76. PubMed ID: 24344319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date.
    Felten R; Scher F; Sagez F; Chasset F; Arnaud L
    Drug Des Devel Ther; 2019; 13():1535-1543. PubMed ID: 31190735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I interferon pathway in pediatric systemic lupus erythematosus.
    Zhou Y; Song HM
    World J Pediatr; 2024 Jul; 20(7):653-668. PubMed ID: 38914753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of sifalimumab, an anti-interferon-α monoclonal antibody, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study.
    Takeuchi T; Tanaka Y; Matsumura R; Saito K; Yoshimura M; Amano K; Atsumi T; Suematsu E; Hayashi N; Wang L; Tummala R
    Mod Rheumatol; 2020 Jan; 30(1):93-100. PubMed ID: 30791804
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-17 in systemic lupus erythematosus: A comprehensive review.
    Li D; Guo B; Wu H; Tan L; Chang C; Lu Q
    Autoimmunity; 2015; 48(6):353-61. PubMed ID: 25894789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Lupus Erythematosus--A Disease with A Dysregulated Type I Interferon System.
    Hagberg N; Rönnblom L
    Scand J Immunol; 2015 Sep; 82(3):199-207. PubMed ID: 26099519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus.
    Luo S; Wang Y; Zhao M; Lu Q
    Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.
    Jones SA; Morand EF
    Drugs; 2024 Jun; 84(6):625-635. PubMed ID: 38807010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update.
    Chaichian Y; Strand V
    Clin Rheumatol; 2021 Aug; 40(8):3027-3037. PubMed ID: 33411137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.